Please select the option that best describes you:

How do you differentiate cognitive impairment from normal age-related cognitive decline?  

Especially in the era of novel AD biomarkers (blood-based, CSF, PET scans), AD treatments, and new definitions of Alzheimer's (Alz Association 2025) - possible to develop "preclinical AD" with just a biomarker.

Any resources for how to counsel patients in this new era would be very helpful...



Answer from: at Academic Institution
Sign In or Register to read more

Answer from: at Community Practice
Sign In or Register to read more